In 212 patients with moderate to severe indolent systemic mastocytosis in the phase 2 PIONEER trial, avapritinib versus placebo reduced skin lesion area (-36.6% vs -1.8%; n=111 with photos) and improved skin symptom scores (-7.2 vs -2.8; P<.0001).
RCTn = 212 patients
Siebenhaar et al. Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study